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Inhibition of growth and induction of differentiation of
metastatic melanoma cells in vitro by genistein:
chemosensitivity is regulated by cellular p53
S Rauthl,2, J Kichina12 and A Green1
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Summary We have investigated the effect of the soybean isoflavone genistein on the growth and differentiation of human melanoma cells.
Four human melanoma cell lines, either completely lacking or containing different levels of wild-type p53, were treated with genistein in vitro
in culture. It has been found that genistein significantly inhibited cell growth and that the chemosensitivity might depend on cellular p53
content. Specifically, the data suggest that high levels of wild-type p53 expression make cells resistant to genistein's growth-inhibitory action.
Further support for this observation came from the stable transfection studies in which p53 transfectants expressing high levels of wild-type
p53 became resistant to genistein. With respect to cell differentiation, our study showed that genistein increased melanin content and
tyrosinase activity and caused the cells to form dendrite-like structures. Cells lacking p53 responded more than cells with p53 to dendrite-like
structure formation. We also observed that genistein-induced differentiation involved an increase in tyrosinase mRNA level; the mechanisms
by which genistein increases tyrosinase transcripts remain to be elucidated. Genistein treatment of the melanoma cell lines resulted in cell
cycle arrest at G2/M check point and no significant apoptosis was observed.
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Currently, the incidence ofmalignant melanoma is on the rise. The
increase in the number ofmelanomas diagnosed has been found to
be greater than for any other cancer except lung cancer in women
(Brozena et al, 1993). Melanomas are readily treatable during the
early stages of development, but the prognosis is grave once the
disease metastasizes. Currently available therapies are not effec-
tive in preventing or curing metastatic spread and morbidity in
patients with this cancer. Better therapeutic and preventive
approaches need to be developed against growth and metastasis of
melanoma.
Epidemiological studies suggest that soy consumption may
contribute to lower rates ofcancers (Nagasawa et al, 1980; Messina
and Barnes, 1991; Messina et al, 1994). One of the hypothesized
candidates against malignancy in soybeans is genistein (4',5,7-tri-
hydroxyisoflavone), a major isoflavone of soybean. Several classes
of compounds in soybeans, like protease inhibitors, saponins,
phytosterols, and isoflavones, have demonstrated anti-cancer
activity. The most recent experimental studies, however, suggest
that genistein may play a major role in mediating the anti-carcino-
genic effects of soybeans (Messina and Barnes, 1991). Purified
genistein inhibited the growth of a wide range of cultured cancer
cells like leukaemia, breast and prostate cancer, and lymphoma
(Constantinou et al, 1990; Kondo et al, 1991; Watanabe et al, 1991;
Peterson and Barnes, 1991, 1993; Pagliacci et al, 1993; Buckley et
al, 1993). In vivo studies also demonstrated that genistein reduced
both the incidence and the multiplicity of DMBA-induced
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mammary tumours and azoxymethane-induced colon tumours in
rats (Lamartiniere et al, 1994; Steele et al, 1995). Among other
enzymes, genistein inhibits the activity of protein tyrosine kinase
(PTK) and topoisomerase II (Akiyama et al, 1987; Markovits et al,
1989). Mechanistically, genistein treatment caused DNA strand
breakage, and DNA breaks were found to be protein linked
(Constantinou et al, 1990; Kiguchi et al, 1990). Under certain treat-
ment conditions, genistein caused cell cycle arrest and apoptotic cell
death in several leukaemia cell lines (Traganos et al, 1992; Spinozzi
et al, 1994). The precise molecular mechanism(s) by which genis-
tein exerts its effects against tumour cells are still not clear.
Recent studies show that both soy and genistein are effective
against skin cancer. Consumption of soybean diets delayed the
onset of skin tumours induced by nitroquinoline-N-oxide and 12-
O-tetradecanoyphorbol-13-acetate (TPA) (Troll et al, 1979). In a
two-stage mouse skin carcinogenesis experiment, the soybean
milk protein reduced both the incidence and the volume of skin
tumours (Limtrakul et al, 1993). Topically applied genistein has
been found to reduce the number of skin carcinomas induced by
DMBA and TPA in CDI mice (Bowen et al, 1993). The topical
application of genistein also inhibited TPA-induced increases
in hydrogen peroxide production in a mouse skin model (Wei
et al, 1993, 1995). A more recent study showed that dietary
genistein significantly enhanced antioxidant enzyme activities
in skin (Cai et al, 1996).
In the present study, we examined the effect ofgenistein on the
growth and differentiation of melanoma that arises from normal
melanocytes commonly located in skin. We used four human
melanoma cell lines that either completely lack or contain
different levels of wild-type p53 as described earlier (Rauth et al,
1994a, b). The differentiated state of the cells was characterized
morphologically and by tyrosinase gene expression and melanin
content. The results showed that genistein significantly inhibited
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growth and induced differentiation ofhuman melanoma in culture.
The results also suggested that the chemosensitivity of the cells
might depend on cellular p53 content. Cells either lacking or
containing low p53 protein levels were more sensitive to
genistein-induced growth arrest than cells with high p53. Further
support for these observations came from gene transfer studies, in
which stable transfectants expressing high levels of wild-type
p53 became resistant to genistein's growth-inhibitory action.
With respect to differentiation, we found that melanoma cells
not expressing p53 were more sensitive to genistein-induced
dendrite-like structure formation than cells expressing high p53.
Our study also showed that genistein-induced differentiation was
associated with an increase in tyrosinase mRNA level. The mech-
anism(s) by which genistein increases tyrosinase transcripts
remain(s) to be elucidated. Genistein treatment of the melanoma
cell lines resulted in arrest ofG2/M check point ofcell cycle distri-
bution and no significant apoptosis was observed.
MATERIALS AND METHODS
Cells and media
The human melanoma cell lines, UISO-MEL-6, UISO-MEL-4,
UISO MEL-7 and UISO-MEL-8, established and characterized in
our laboratory (Rauth et al, 1994a, b), have been used in the present
study. All cells were maintained in MEM-H [minimum essential
medium with Hanks' balanced salt solution (Gibco, Grand Island,
NY, USA)] containing fetal calf serum (2%), L-glutamine (1%),
non-essential amino acids and penicillin-streptomycin (0.2%).
Plasmids and reagents
The human wild-type p53 expression plasmid, pC53-SN3, and
the expression vector without p53 cDNA, pCMVNeo, originally
constructed by Bert Vogelstein (Baker et al, 1990), were obtained
from Professor Kiranur Subramanian. Department of Genetics,
University ofIllinois, Chicago, USA. Genistein was obtained from
Sigma Chemical Co.
Transfection experiments
To isolate cells stably transfected with human wild-type p53
expression plasmid pC53-SN3, UISO-MEL-4 cells were co-trans-
fected with plasmids pC53-SN3 and pIRVGalNeo as described
earlier (Rauth et al, 1993). Three days after transfection, the cells
were subcultured in the presence of 1 mg ml G418 (Sigma
Chemical Co.). The selective media with G418 was replaced every
3 days, and the colonies that appeared after 10-14 days were
pooled and subcultured forfurther analysis. The stable transfectant
was designated as UISO-MEL-4WP. As a control, cells stably
transfected with the expression vector were also isolated similarly.
Western blot analysis
The melanoma cell lines were analysed for p53 protein level by
Westem blot analysis. These cells were then lysed in lysis buffer
containing 50 mM Tris (pH 8.0), 250 mm sodium chloride and 0.1%
Nonidet p-40 as described (Kichina et al, 1996). The cell extracts
containing equal amounts of protein (150 jg) were separated on a
sodium dodecyl sulphate (SDS)-12.5% polyacrylamide gel. The
proteins were transferred electrophoretically to a nitrocellular
membrane, andthep53 proteins intheblotweredetectedwith a 1:200
dilution of p53 monoclonal antibody Ab-2 (pAbl801, Oncogene
Science) andthe enhanced chemiluminescence system (Amersham).
Tyrosinase expression by reverse transcription and
polymerase chain reaction (RT-PCR)
The human melanomacell lines were analysedfortyrosinase expres-
sion at the mRNA level by reverse transcription of the total cellular
RNA and PCR amplification of the reverse-transcribed tyrosinase
transcript using primers specific for human tyrosinase sequences.
The PCR amplification of the reverse-transcribed RNA was
performed in a 100-gl volume with 2.5 U of Taq DNA polymerase
(Promega), using an Eri Comp DNA thermocycler following the
procedure described previously (Kichina et al, 1996). The sequences
of the primers used to amplify tyrosinase cDNA sequences were:
primer 1: 5'-TAGGACCTGCCAGTTGCCTTTCT-3' (sense);
primer 2: 5'-AAGGCATTGTGCATGC-3' (antisense). The
sequences of the primers were obtained from the published report
(Powers et al, 1994) and were synthesized on an ABI model 394
DNA synthesizer. The primer 1 is located on exon 1, whereas
primer 2 is located on exon 2 of the tyrosinase gene, and these
primers amplify a 840-bp cDNA fragment. The control PCR
amplification reaction mixture contained the reagent mixture for
PCR amplification without the added cDNA.
p53 expression by RT-PCR
p53 mRNA was analysed by RT-PCR of total cellular RNA from
the stable transfectants as described earlier (Kichina et al, 1996).
The sequences of the primers used to amplify p53 cDNA are
spaced 1225 nucleotides apart and yield a full-length cDNA frag-
ment. Primer 1: 5'-AGACTGCCTTCCGGGTCACT-3'; primer
2: 5'-GGGAACAAAGAAGTGGAGAAT-3'. P2-Microglobulin
(V2m) mRNA, used as an internal control, was also analysed by
RT-PCR. The sequences of the primers used to amplify I2-
microglobulin were obtained from published sequences (Noonan
et al, 1990) and yielded a 120-bp cDNA fragment.
Flow cytometry
Melanoma cells (1 x 107) were cultured in the presence of
dimethyl sulphoxide (DMSO) or genistein for 0, 24, 44 and 72 h.
Cells were harvested, fixed with ethanol and flow cytometry was
performed after treatment with trypsin and RNAase A as described
previously (Pisha et al, 1995).
RESULTS
Differential effect of genistein on melanoma growth
in vitro
To investigate genistein's effects on melanomacells, we have used
four cell lines (UISO-MEL-6, UISO-MEL-4, UISO-MEL-7 and
UISO-MEL-8) that either lack or contain different levels of wild-
type p53 (Rauth et al, 1994a, b). In our previous study, we have
analysed ten melanoma cell lines for p53 alterations at the DNA,
RNA and protein levels (Rauth et al, 1994a). Nucleotide
sequencing demonstrated no mutations in exons 5 to 8 of the p53
gene in any ofthe cell lines tested. Northern blot analysis showed
60% of the cell lines expressed high levels of p53 mRNA.
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Figure 1 Western blot analysis for p53 protein levels in melanoma cell lines.
Cell extracts containing equal amounts of protein (150 igg) were separated
on a SDS-12.5% polyacrylamide gel. Proteins were transferred
electrophoretically to a nitrocellulose membrane, and the p53 proteins in the
blot were detected with a 1:200 dilution of p53 monoclonal antibody Ab-2
(pAbl 801, Oncogene Science) and the enhanced chemiluminescence
system (Amersham)
Immunocytochemical analysis using antibody specific for wild-
type and mutant p53 protein agreed with the DNA and RNA
analysis data. The cytogenetic analysis of these cell lines showed
that 17p, where p53 is located, is missing in UISO-MEL-6 cell line
owing to isochromosome formation (Rauth et al, 1994b). Taken
together, we found that UISO-MEL-6 completely lacks and UISO-
MEL-4 contains a very low level ofwild-type p53 protein. On the
other hand, UISO-MEL-7 and UISO-MEL-8 express moderate
and high levels of wild-type p53 protein respectively. In the
present study, the levels of p53 protein in the melanoma cell lines









were quantified by Western blot analysis. As shown in Figure 1,
different levels of p53 protein are present in four cell lines that
agree with our previous data. To test the functionality of endoge-
nous wild-type p53 protein in these cell lines, a number ofexperi-
ments using transient transfection approaches and a construct
containing CAT reporter gene ligated to p53-responsive p21
promoter sequences have been done. Ourpreliminary experiments
showed that endogenous p53 in these cell lines might be functional
and could induce CAT gene expression from a p53-responsive
element (data not shown).
The four cell lines, either lacking or containing various p53
levels, were treated with different concentrations ofgenistein, and
the cell numbers were counted for 9 days (renewing the culture
with fresh media every 3 days). As shown in Figure 2, genistein
significantly inhibited the growth of melanoma cells. The growth
rates of UISO-MEL-6 and UISO-MEL-4, which lack and contain
very low wild-type p53 respectively, were very sensitive to genis-
tein. A concentration of genistein as low as 10 gM significantly
inhibited the growth of those cells in culture. In contrast, UISO-
MEL-7 (moderate p53) and UISO-MEL-8 (high p53) were less
sensitive to genistein. UISO-MEL-8 cells, which contain a high
level of wild-type p53, were considerably resistant to genistein's
growth-inhibitory effects. With 10-60 gM genistein, those cells
Days
UISO-MEL-8 (Wt p53 high level)
. ~~~~~~~~~~--
Days
-n-Control -+-10 MGT --60 gMGT
Figure 2 Effect of genistein (GT) on growth of four human melanoma cell lines containing different levels of p53. Melanoma cells growing exponentially were
plated in triplicate at a density of 1 x 104 cells per well in multiwell dishes with MEM-E and 10% fetal bovine serum (FBS), and cultured for 9 days in the absence
and presence of genistein. Cultured media were renewed every 3 days
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Figure 3 Increase in tyrosinase mRNA expression in UISO-MEL-7 cells
treated for 6 days with 10 gM and 30 gM genistein. Tyrosinase mRNA was
analysed by reverse transcription and polymerase chain reaction (RT-PCR).
Different volumes of RT-PCR mix (2, 4 and 8 gl) of each sample was loaded
on 1% agarose gel. Lanes 1, 2 and 3, untreated cells; lanes 4, 5 and 6, 10 gM
genistein-treated cells; lanes 7, 8 and 9, 30 gM genistein-treated cells
grew almost at the same rate as the untreated cells. These data
suggest that genistein inhibits melanoma growth in vitro and that
growth inhibition is more pronounced in cell lines eitherlacking or
with low p53.
Genistein induces differentiation and activates
tyrosinase expression at the mRNA level
Genistein's effects on the differentiation of melanoma cell lines
containing different levels of p53 were examined. The induction of
differentiation and acquiring of mature phenotype were character-
ized by the production of melanin, increase in tyrosinase expression
and formation of dendrite-like cellular protrusions. In culture, cells
were treated with 10 gM and 60 gM genistein for 9 days, and cells
were analysed for changes in tyrosinase expression and morphology.
This study demonstrated a dose- and and time-dependent increase in
pigmentation (visually detectable) and tyrosinase activity (analysed
by the DOPA method, data not shown). The increase in tyrosinase
activity was associated with an increase in the tyrosinase mRNA
level. The tyrosinase mRNA was analysed by reverse transcription
and polymerase chain reaction (RT-PCR) using tyrosinase gene-
specific primers, which yielded an 840-bp tyrosinase cDNA frag-
ment. As shown in Figure 3, increased levels oftyrosinasetranscripts
were detected in UISO-MEL-7 melanoma cells following treatment
with 10 gM and 30 gM genistein for 6 days. [2-Microglobulin
mRNA, used as an internal control, remained unchanged in the
genistein-treated cells (data not shown). These results indicate that
genistein induces differentiation and enhances tyrosinase expression
at the mRNA level.
The differentiated state of melanoma cells was then monitored
by the formation of dendrite-like cellular protrusions. The
melanoma cell lines containing different levels ofp53 were treated
with genistein of different concentrations, and the cells were
examined for changes in morphology. As shown in Figure 4, the
treatment of melanoma cell lines, MEL-6 (pS3 negative) and
MEL-7 (p53 positive), with 10 gM and 60 gM genistein caused the
cells to form dendrite-like structures. These dendritic structures
became progressively longer, and by 6 days after treatment, more
than 90% of the cells showed an extensive network of such struc-
tures. The cell lines either lacking p53 or with low p53 became
more dendritic than those containing a high level ofp53.
Effect of exogenous p53 on chemosensitivity
To analyse the relationship between genistein's growth-suppres-
sion function and p53 levels of the cells, we made a stable
melanoma cell line overexpressing wild-type p53. UISO MEL-4,
containing a low level of wild-type p53, was stably transfected
with wild-type p53 expression plasmid (pC53-SCN3), and the
stable transfectants were selected by G418 resistance. As a
control, the expression vector without p53 cDNA insert
(pCMVNeo) was also stably transfected into the same line under
the same conditions. The number of G418-resistant colonies
obtained with the wild-type p53 was found to be slightly lower
than that obtained with the expression vector. UISO-MEL-6,
which completely lacks p53, was also transfected with the wild-
type p53 expression plasmid under the same conditions, but no
G418-resistant colonies with wild-type p53 survived.
A pool of UISO-MEL-4 stable transfectants was analysed for
p53 protein level by Western blot analysis with p53 monoclonal
antibody Ab-2 (PAb1801, Oncogene Science). As shown in Figure
5A, the stable transfectants, MEL-4 WP, expressed a high level of
p53 protein compared with the parental MEL-4 cells.
To determine whether p53 mRNA is transcribed from the trans-
fected plasmid, transfectants were analysed for p53 mRNA levels
by reverse transcription and polymerase chain reaction. As shown
in Figure SB, increased levels of p53 mRNA were detected in
the stable transfectants compared with untransfected cells. 2-
Microglobulin (P2-m) mRNA, used as an internal control, remained
unchanged in the transfectants.
To test the functionality of wild-type p53 in the stable transfec-
tant, we have examined the levels of p21 mRNA. Expression of
p21 gene is known to be induced directly by wild-type p53
(El-Diery et al, 1993). Our study showed that the p53 stable trans-
fectants expressed a high level ofp21 mRNA or protein (data not
shown). We have also tested whether wild-type p53 in the stable
transfectant could induce CAT gene expression from p53-respon-
sive p21 promoter sequences in transient transfection assays. Our
preliminary data showed that the stable transfectants demonstrated
a higher level of CAT activity compared with that in the parental
MEL-4 cells (data not shown). These results suggested that p53 in
the stable transfectant was wild-type and functional.
To examine genistein's effects on the growth of the stable trans-
fectants, cells were treated with 10 gM and 60 JIM genistein in
culture. As shown in Figure SC, the stable transfectants over-
expressingp53 became resistant togenistein at the 10gMconcentra-
tion. Only a small decrease in the growth rate ofstable transfectant,
MEL-4 Wp, was detected, whereas parental MEL-4 cells demon-
strated significant growth inhibition following genistein treatment.
These results suggest thatexpression ofhigh levels ofwild-type p53
make melanomacells resistant to genistein-induced growth arrest.
To determine whether genistein treatment of melanoma cells
resulted in alteration of cell cycle progression, the cell cycle
patterns of the melanoma cell lines were examined by flow cyto-
metric analysis. At a 60gMconcentration, genistein arrested G2/M
phase in all four cell lines. Figure 6 shows cell cycle dynamics of
MEL-6 and MEL-4 cells untreated or treated with genistein. At a
lower concentration of genistein (30 gM), small changes in the
cell cycle distribution at G2/M phase were observed. The stable
transfectant, MEL-4 WP, also showed delay in G2/M phase.
Actinomycin D (1 ng ml') treatment, on the other hand, showed
delay in both G,/Go and G2/M phases in MEL-4 WP and G2/M in
parental MEL-4 cells (data not shown). Only a very small
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Figure 4 Dendrite-like structure formation in UISO-MEL-6 (p53 negative) and UISO-MEL-7 (p53 positive) cells treated for 6 days with 10gM and 60gM
genistein. (A-C) UISO-MEL-6 cells; (D-F) UISO-MEL-7 cells. Cell morphology was visualized by light microscopy. (A and D) untreated cells; (B and E) 10gM
genistein-treated cells; (C and F) 60M genistein-treated cells
apoptotic peak was detected in genistein (60 JM)-treated
melanoma cells analysed flow cytometrically.
DISCUSSION
The data presented in this report demonstrate that genistein can
arrest growth and enhance differentiation of metastatic melanoma
cells; more importantly, the chemosensitivity of these cells may be
regulatedbycellularp53. Weusedfourcell lines thathavebeen well
characterized forp53 at DNA, RNA and protein levels (Rauth et al,
1994a, b). Theresults presentedhere showed thatthegrowth ofcells
either negative (UISO-MEL-6) or low (UISO-MEL-4) in wild-type
p53 was almost completely inhibited when treated with genistein. In
contrast, only a small decrease in growth rate was observed in
melanoma cells containing ahigh level ofwild-type p53.
The melanoma cell lines were originally derived from the biop-
sies of different patients (Rauth et al, 1994b) and may differ in
factors besides the endogenous p53 content. To investigate
whether the differential effect ofgenistein on cell growth is related
to the levels of endogenous p53, we stably transfected the
melanoma cell line MEL-4 with wild-type p53 expression
plasmid. The functionality of wild-type p53 expressed in the
stable transfectant was tested by an increase in endogenous p21
expression. To determine the effects of genistein, parental cells
containing very low levels of endogenous wild-type p53, and the
transfectants expressing high levels of p53, were treated with
different doses ofgenistein. The data presented in Figure 5 clearly
show that p53 transfectants became significantly less sensitive
than the parental cells to genistein's growth-inhibitory effects.
As a corollary to our observations, a recent study reported that
genistein induced endogenous p53 levels in several tumour cell
lines (El-Deiry et al, 1994). Previous studies have demonstrated that
genistein caused single- and double-strand DNA breaks in tumour
cells (Constantinou et al, 1990; Kiguchi et al, 1990). Many cancer
chemotherapeutic drugs and ultraviolet light or gamma-irradiation,
which damage DNA, are known to induce accumulation ofnormal
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Figure 5 Expression of exogeneous p53 in UISO-MEL-4 melanoma cells and its effect on genistein-induced growth arrest. (A) Expression of p53 protein in
MEL-4WP, the stable transfectant derived from MEL-4 melanoma cells. MEL-4 cells were transfected with wild-type p53 expression plasmid (pC53-SCN3), and
the stable transfectants were selected by G418 resistance. A pool of stable transfectants was analysed for p53 by Western blot analysis with p53 monoclonal
antibody Ab-2 (PAbl801, Oncogene Science). Lane 1 shows p53 from parental MEL-4 cells; lane 2 shows p53 from stable transfectant MEL-4WP.
(B) Expression of p53 mRNA in the stable transfectants. The levels of mRNA were analysed by reverse transcription and polymerase chain reaction (RT-PCR)
of total cellular RNA. The sequences of the primers used to amplify p53 cDNA were spaced 1225 nucleotides apart, spanning the entire coding region of the
gene. 02-Microglobulin mRNA was analysed by RT-PCR using a primer pair that yields a 120-bp fragment. (C) Differential effect of genistein on growth of
MEL-4 WP and MEL-4 cell lines. Treatment with 10 gm genistein decreased MEL-4 cell numbers by 95% of control value, whereas only 30% reduction occurred
with MEL-4 WP
p53 in the cells (Kastan et al, 1991, 1992; Lowe et al, 1993; El- through the G2/M phases of the cell cycle. It also suppressed the
Deiry et al; 1994). This accumulation ofp53, in turn, mediates cell early portion ofthe G1 phase in human leukaemia MOLT-4 cells by
cycle arrest at the G, phase or programmed cell death. In several approximately 40%. In our cell cycle studies, we have demonstrated
tumour cell lines, genistein arrested cell cycle progression and that addition of genistein arrested progression through the G/M
caused apoptotic cell death (Traganos et al, 1992; Spinozzi et al, phases in four melanoma cell lines. Figure 6 represents the' cell
1994). In HL-60 human leukaemia cells, it arrested progression cycle distribution of MEL-4 and MEL-6 melanoma cell lines. The
British Journal ofCancer (1997) 75(11), 1559-1556
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Figure 6 Effect of genistein on cell cycle distribution of melanoma cell lines
determined by flow cytometry. Mel-4 and Mel-6 cells (1 x 106) were grown in
the presence of genistein (60gM) for 24, 44 and 72 h. As a control, cells
(1 x 106) were also grown in the presence of DMSO under the same
conditions. The cells were analysed for cell cycle distribution by flow
cytometry as described in Materials and methods. The cell cycle distributions
of melanoma cell lines treated with DMSO or genistein for 44 h are shown in
this figure. The sub-G, apoptotic peak is labelled Ap
p53 stable transfectant MEL-4 WP also showed delay in progres-
sion through the G2/M phases. No significant apoptosis was
observed in any of the cell lines treated with 60 ,UM genistein.
Actinomycin D, which is also known to cause DNA damage,
arrested both GI/Go and G2IM phases in the stable transfectant
MEL-4WP and only G/M in the parental MEL-4. Whether genis-
tein mediates its action in a different pathway from other DNA-
damaging agents needs to be investigated.
With respect to cell differentiation, our studies indicate that
genistein induced human melanoma cell lines to undergo terminal
differentiation at a concentration ranging from 10 to 60gM.
Significantly more dendritic structures were observed inp53-nega-
tive cells compared with those in p53-positive cells. Genistein-
induced differentiation involved an increase in tyrosinase
expression at the mRNA level. The mechanism(s) by which the
tyrosinase mRNA level is increased are still not known. Recently,
we demonstrated that bromodeoxyuridine (BrdU), which
suppresses differentiation in melanoma, suppressed tyrosinase
expression atthe mRNA level (Rauth et al, 1990). The suppression
oftyrosinase mRNA involved suppression of tyrosinase promoter
activity (Rauth et al, 1993). Itis possible thatgenistein mediates its
effects through similar mechanism(s), but additional experiments
are required to investigate these possibilities.
In summary, the present observations show that genistein is able
to inhibit growth and induce differentiation in human melanoma
cells in vitro. The effects ofgenistein may depend on the levels of
endogenous p53 in the cells. It is not surprising that we found p53-
negative cells were more sensitive to genistein's effects. p53 is
known to induce DNA repair enzymes, and cells containing wild-
type p53 may have repair ofthe DNA damage caused by genistein
treatment. Tumour cells, either deficient in p53 or with very low
doses ofit, replicate through the damage and are more susceptible
to genistein's effects. A recent report by Elledge et al (1995), who
noted that patients with breast cancer in whom there were p53-
negative cells tended to receive greaterbenefit from chemotherapy
with different drugs, including DNA-damaging agents, supports
our observation. Genistein inhibits the growth of tumour cells in
vivo (Lamartiniere et al, 1994) and has been proved to be non-
toxic in animals (Faber et al, 1991; Schweigerer et al, 1992). Both
soybean and genistein have been found to be effective in reducing
skin carcinogenesis (Troll et al, 1979; Limtrakul et al, 1993;
Bowen et al, 1993; Wei et al, 1993, 1995; Cai et al, 1996). These
reports provide a good basis for further evaluation of genistein in
vivo for treating or preventing melanoma that contains cells with
different p53 status.
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